Characterization and Immunogenicity of Influenza H7N9 Vaccine Antigens Produced Using a Serum-Free Suspension MDCK Cell-Based Platform
Human infections with avian-origin H7N9 influenza A viruses were first reported in China, and an approximately 38% human mortality rate was described across six waves from February 2013 to September 2018. Vaccination is one of the most cost-effective ways to reduce morbidity and mortality during inf...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-08-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/14/9/1937 |
| _version_ | 1797481414869909504 |
|---|---|
| author | Min-Yuan Chia Chun-Yang Lin Po-Ling Chen Chia-Chun Lai Tsai-Chuan Weng Wang-Chou Sung Alan Yung-Chih Hu Min-Shi Lee |
| author_facet | Min-Yuan Chia Chun-Yang Lin Po-Ling Chen Chia-Chun Lai Tsai-Chuan Weng Wang-Chou Sung Alan Yung-Chih Hu Min-Shi Lee |
| author_sort | Min-Yuan Chia |
| collection | DOAJ |
| description | Human infections with avian-origin H7N9 influenza A viruses were first reported in China, and an approximately 38% human mortality rate was described across six waves from February 2013 to September 2018. Vaccination is one of the most cost-effective ways to reduce morbidity and mortality during influenza epidemics and pandemics. Egg-based platforms for the production of influenza vaccines are labor-intensive and unable to meet the surging demand during pandemics. Therefore, cell culture-based technology is becoming the alternative strategy for producing influenza vaccines. The current influenza H7N9 vaccine virus (NIBRG-268), a reassortant virus from A/Anhui/1/2013 (H7N9) and egg-adapted A/PR/8/34 (H1N1) viruses, could grow efficiently in embryonated eggs but not mammalian cells. Moreover, a freezing-dry formulation of influenza H7N9 vaccines with long-term stability will be desirable for pandemic preparedness, as the occurrence of influenza H7N9 pandemics is not predictable. In this study, we adapted a serum-free anchorage-independent suspension Madin-Darby Canine Kidney (MDCK) cell line for producing influenza H7N9 vaccines and compared the biochemical characteristics and immunogenicity of three influenza H7N9 vaccine antigens produced using the suspension MDCK cell-based platform without freeze-drying (S-WO-H7N9), the suspension MDCK cell-based platform with freeze-drying (S-W-H7N9) or the egg-based platform with freeze-drying (E-W-H7N9). We demonstrated these three vaccine antigens have comparable biochemical characteristics. In addition, these three vaccine antigens induced robust and comparable neutralizing antibody (NT; geometric mean between 1016 and 4064) and hemagglutinin-inhibition antibody (HI; geometric mean between 640 and 1613) titers in mice. In conclusion, the serum-free suspension MDCK cell-derived freeze-dried influenza H7N9 vaccine is highly immunogenic in mice, and clinical development is warranted. |
| first_indexed | 2024-03-09T22:14:14Z |
| format | Article |
| id | doaj.art-57ea496f076d40e39ec5652f6f90d8ab |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-09T22:14:14Z |
| publishDate | 2022-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-57ea496f076d40e39ec5652f6f90d8ab2023-11-23T19:26:44ZengMDPI AGViruses1999-49152022-08-01149193710.3390/v14091937Characterization and Immunogenicity of Influenza H7N9 Vaccine Antigens Produced Using a Serum-Free Suspension MDCK Cell-Based PlatformMin-Yuan Chia0Chun-Yang Lin1Po-Ling Chen2Chia-Chun Lai3Tsai-Chuan Weng4Wang-Chou Sung5Alan Yung-Chih Hu6Min-Shi Lee7Department of Veterinary Medicine, National Chung Hsing University, Taichung 40227, TaiwanNational Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan 35053, TaiwanNational Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan 35053, TaiwanNational Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan 35053, TaiwanNational Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan 35053, TaiwanNational Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan 35053, TaiwanNational Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan 35053, TaiwanNational Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan 35053, TaiwanHuman infections with avian-origin H7N9 influenza A viruses were first reported in China, and an approximately 38% human mortality rate was described across six waves from February 2013 to September 2018. Vaccination is one of the most cost-effective ways to reduce morbidity and mortality during influenza epidemics and pandemics. Egg-based platforms for the production of influenza vaccines are labor-intensive and unable to meet the surging demand during pandemics. Therefore, cell culture-based technology is becoming the alternative strategy for producing influenza vaccines. The current influenza H7N9 vaccine virus (NIBRG-268), a reassortant virus from A/Anhui/1/2013 (H7N9) and egg-adapted A/PR/8/34 (H1N1) viruses, could grow efficiently in embryonated eggs but not mammalian cells. Moreover, a freezing-dry formulation of influenza H7N9 vaccines with long-term stability will be desirable for pandemic preparedness, as the occurrence of influenza H7N9 pandemics is not predictable. In this study, we adapted a serum-free anchorage-independent suspension Madin-Darby Canine Kidney (MDCK) cell line for producing influenza H7N9 vaccines and compared the biochemical characteristics and immunogenicity of three influenza H7N9 vaccine antigens produced using the suspension MDCK cell-based platform without freeze-drying (S-WO-H7N9), the suspension MDCK cell-based platform with freeze-drying (S-W-H7N9) or the egg-based platform with freeze-drying (E-W-H7N9). We demonstrated these three vaccine antigens have comparable biochemical characteristics. In addition, these three vaccine antigens induced robust and comparable neutralizing antibody (NT; geometric mean between 1016 and 4064) and hemagglutinin-inhibition antibody (HI; geometric mean between 640 and 1613) titers in mice. In conclusion, the serum-free suspension MDCK cell-derived freeze-dried influenza H7N9 vaccine is highly immunogenic in mice, and clinical development is warranted.https://www.mdpi.com/1999-4915/14/9/1937influenza H7N9 vaccinesuspension MDCK cellimmunogenicity |
| spellingShingle | Min-Yuan Chia Chun-Yang Lin Po-Ling Chen Chia-Chun Lai Tsai-Chuan Weng Wang-Chou Sung Alan Yung-Chih Hu Min-Shi Lee Characterization and Immunogenicity of Influenza H7N9 Vaccine Antigens Produced Using a Serum-Free Suspension MDCK Cell-Based Platform Viruses influenza H7N9 vaccine suspension MDCK cell immunogenicity |
| title | Characterization and Immunogenicity of Influenza H7N9 Vaccine Antigens Produced Using a Serum-Free Suspension MDCK Cell-Based Platform |
| title_full | Characterization and Immunogenicity of Influenza H7N9 Vaccine Antigens Produced Using a Serum-Free Suspension MDCK Cell-Based Platform |
| title_fullStr | Characterization and Immunogenicity of Influenza H7N9 Vaccine Antigens Produced Using a Serum-Free Suspension MDCK Cell-Based Platform |
| title_full_unstemmed | Characterization and Immunogenicity of Influenza H7N9 Vaccine Antigens Produced Using a Serum-Free Suspension MDCK Cell-Based Platform |
| title_short | Characterization and Immunogenicity of Influenza H7N9 Vaccine Antigens Produced Using a Serum-Free Suspension MDCK Cell-Based Platform |
| title_sort | characterization and immunogenicity of influenza h7n9 vaccine antigens produced using a serum free suspension mdck cell based platform |
| topic | influenza H7N9 vaccine suspension MDCK cell immunogenicity |
| url | https://www.mdpi.com/1999-4915/14/9/1937 |
| work_keys_str_mv | AT minyuanchia characterizationandimmunogenicityofinfluenzah7n9vaccineantigensproducedusingaserumfreesuspensionmdckcellbasedplatform AT chunyanglin characterizationandimmunogenicityofinfluenzah7n9vaccineantigensproducedusingaserumfreesuspensionmdckcellbasedplatform AT polingchen characterizationandimmunogenicityofinfluenzah7n9vaccineantigensproducedusingaserumfreesuspensionmdckcellbasedplatform AT chiachunlai characterizationandimmunogenicityofinfluenzah7n9vaccineantigensproducedusingaserumfreesuspensionmdckcellbasedplatform AT tsaichuanweng characterizationandimmunogenicityofinfluenzah7n9vaccineantigensproducedusingaserumfreesuspensionmdckcellbasedplatform AT wangchousung characterizationandimmunogenicityofinfluenzah7n9vaccineantigensproducedusingaserumfreesuspensionmdckcellbasedplatform AT alanyungchihhu characterizationandimmunogenicityofinfluenzah7n9vaccineantigensproducedusingaserumfreesuspensionmdckcellbasedplatform AT minshilee characterizationandimmunogenicityofinfluenzah7n9vaccineantigensproducedusingaserumfreesuspensionmdckcellbasedplatform |